Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

Inclusion Criteria: * Male or female greater than 18 years of age * Chronic Kidney Disease (CKD) not yet requiring renal replacement therapy (pre-dialysis patients) * Not expected to require dialysis during duration of the study * Adequate laboratory values * If on rHuEPO therapy, the dose must be stable Exclusion Criteria: * Persistent chronic or active infections * Intravenous (IV) iron administration within 12 weeks prior to the Screening Visit * Known history of severe uncontrolled hyperparathyroidism * Prior recipient or scheduled to receive a kidney transplant during the study * Abnormal laboratory values * Unstable angina or myocardial infarction within the past 6 months prior to the Screening Visit * Uncontrolled hypertension * Coronary disease diagnosed in the 3 months prior to the Screening Visit * Severe Congestive Heart Failure * History of HIV * Hepatitis B and/or Hepatitis C * Abnormal chest radiograph * A positive intradermal skin tuberculin test * History or presence of cancer within 5 years of the Screening Visit * History of alcohol abuse or current intake of 21 or more alcohol-containing drinks per week * History of drug abuse within the 5 years prior to the Screening Visit * Lactating females or pregnant females